Braveheart Bio, Inc. (BRVE) Stock Ticker
BRVE right now
Market factors today
Unlock the full BRVE picture
About Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
BRVE stock facts
| Ticker symbol | BRVE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.5B |
| CEO | Travis Murdoch |
| Employees | 49 |
| Headquarters | San Francisco, CA, US |
| IPO date | 2026-08-06 |
| Website | www.braveheart.bio |
What you can see for BRVE on Tickr
Live BRVE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BRVE report.
Rankings
FAQ
What is the ticker symbol for Braveheart Bio, Inc.?
The ticker symbol for Braveheart Bio, Inc. is BRVE, listed on the NASDAQ.
What is BRVE?
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.